KR20220055887A - Pharmaceutical composition for the prevention or treatment of sarcopenic obesity containing Ecklonia cava extract - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating sarcopenic obesity containing an ecklonia cava extract. The ecklonia cava extract according to the present invention increases a muscle amount of a patient with the sarcopenic obesity, and reduces a fat amount accumulated in muscle tissues at the same time. By increasing a proportion of muscles in the total weight and reducing the fat amount accumulated in the muscles, oxidative stress or an inflammatory reaction caused from fat accumulated in the muscles is suppressed. By preventing damage of muscle cells and tissues and restoring functions of muscle cells and the tissues of the patient, the sarcopenic obesity is improved or treated. By ultimately reducing a risk of a metabolic disease or a cardiovascular disease, the present invention can improve quality of a life of the patient.

Description

Pharmaceutical composition for the prevention or treatment of sarcopenic obesity containing Ecklonia cava extract {Pharmaceutical composition for the prevention or treatment of sarcopenic obesity containing Ecklonia cava extract}

The present invention relates to a pharmaceutical composition for preventing or treating sarcopenic obesity containing Ecklonia cava extract.

Recently, the rapid increase of the obese population around the world has become a problem. Obesity causes many problems by accumulating fat throughout the body, but with it, a decrease in muscle mass is also a major problem. The prevalence is higher in sarcopenic obesity, which has a complex form of obesity and sarcopenia rather than simple obesity. It is reported to increase the risk of death, and recently, studies related to sarcopenic obesity are increasing.

In the case of sarcopenic obesity, in addition to adipose tissue, inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, etc.) increase from intramuscular fat accumulation, which inhibits muscle protein metabolism, causing a decrease in muscle mass, and also insulin By increasing resistance, physical activity decreases and basal metabolic rate decreases, which in turn acts in the direction of increasing body fat mass, causing a vicious cycle. Sarcopenic obesity leads to a decrease in muscle mass and muscle function, which eventually leads to problems such as falls, dysfunction, reduced quality of life, and increased mortality, as well as increases the risk of cardiovascular disease and metabolic disorders.

According to a study using data from the Korean Longitudinal Study on Health and Aging (KLoSHA) for the prevalence of sarcopenic obesity, the diagnosis of obesity was made when the area of fat in the abdominal cavity exceeds 100 cm ² on abdominal CT. When sarcopenia was diagnosed with ASM/Wt, it was reported in 35.1% of men and 48.1% of women, and when the risk of metabolic syndrome was calculated by regression analysis using ASM/Wt as an index of sarcopenia, the odds ratio was calculated in the normal group. On the other hand, the sarcopenic obesity group showed an odds ratio of 8.2 times and that of the obese group 5.5 times, indicating that the prevalence of sarcopenic obesity was higher than that of simple obesity (Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652-4.). As such, sarcopenic obesity has a higher prevalence than simple obesity, and is found to be a cause of increasing the prevalence of metabolic diseases, etc. not only in the elderly population but also in the young.

Accordingly, although efforts are being made to diagnose and actively treat sarcopenic obesity at an early stage or to maintain a healthy life of the patient by minimizing changes in body composition, many studies are still required for the diagnosis and treatment of sarcopenic obesity. There is no suitable therapeutic agent for sarcopenic obesity yet.

On the other hand, Ecklonia cava is a plant of the Laminariales family of brown algae, and is mainly inhabited in Korea at a depth of about 10m along the coast of Jeju. As a study using Ecklonia, it is being studied in terms of antioxidant, anticancer, and antiobesity, and it is reported that it has sufficient value as a new functional material. In particular, phlorotannin, a major component of Ecklonia, is a polyphenol compound with phloroglucinol as a basic structural unit. has been reported to represent However, there has been no report confirming the use of Ecklonia extract for muscle improvement or the effect on sarcopenic obesity.

Under the above background, the present inventors, while trying to develop a therapeutic agent for muscular strength improvement and sarcopenic obesity, Ecklonia cava extract increases the muscle mass of the sarcopenic obese animal model while simultaneously reducing the amount of fat accumulated in the muscle tissue. , by restoring the function of the muscle, it was confirmed that it can be used as a drug for the prevention or treatment of sarcopenic obesity and as a health functional material, the present invention has been completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

Another object of the present invention is to provide a health functional food composition for preventing or improving sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

Another object of the present invention is to provide a health functional food composition for improving muscle function containing Ecklonia cava extract as an active ingredient.

In order to achieve the above purpose,

The present invention provides a pharmaceutical composition for preventing or treating sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

In addition, the present invention provides a health functional food composition for preventing or improving sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

Furthermore, the present invention provides a health functional food composition for improving muscle function containing Ecklonia cava extract as an active ingredient.

The Ecklonia cava extract according to the present invention can increase the muscle mass of sarcopenic obese patients and at the same time reduce the amount of fat accumulated in the muscle tissue. By reducing the amount of fat produced, it is possible to suppress the oxidative stress or inflammatory response caused by fat accumulating in the muscle, and to prevent damage to muscle cells and tissues, thereby restoring the function of the muscle cells and tissues of the patient. It can improve or treat sexual obesity, and ultimately reduce the risk of developing metabolic diseases or cardiovascular diseases, thereby having a useful effect of improving the quality of life of patients.

1 is a graph showing the yield (%) of Ecklonia cava extract extracted using 40%, 50%, or 70% ethanol in Example 1, respectively.
Figure 2 is a graph confirming the change in the muscle mass in the total body weight by concurrently ingesting Ecklonia cava extract in sarcopenic obese animals consuming a high-fat diet.
3 is a graph confirming the weight change of (A) calf muscle and (B) fluke muscle of the animal by concurrent ingestion of Ecklonia cava extract in sarcopenic obese animals consuming a high-fat diet.
Figure 4 is a graph confirming the change in grip strength of the animal by concurrently ingesting Ecklonia cava extract in sarcopenic obese animals consuming a high-fat diet.
5 is an image showing the results of (A) Oil-Red O staining in the muscle tissue of an animal by concurrent ingestion of Ecklonia cava extract in sarcopenic obese animals consuming a high-fat diet and the change in fat accumulation in the muscle tissue measured therefrom. It is the confirmed (B) graph.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

In the present invention, " Ecklonia cava " is a plant of the brown algae plant, Laminariales, of the seaweed family. It is known to inhabit in Korea, mainly on the coast of Jeju at a depth of about 10 m, and also in Japan, and has a length of 1 to 2 m. The stem is cylindrical and the base is in the shape of a root.

The Ecklonia cava may be whole or partial. The part may be an above-ground part or an underground part.

In one aspect of the present invention, the Ecklonia cava extract can be prepared using a conventionally known extraction method of a plant extract without limitation.

In one aspect of the present invention, the Ecklonia cava extract can be prepared as follows. The Ecklonia cava extract can be extracted from the whole, or at least a part, of the Ecklonia cava plant using an extraction medium, for example, an inorganic or organic material in a gaseous or liquid phase, or a mixture thereof, but is not limited thereto, As one embodiment, it can be obtained using a conventional extraction solvent, for example, (a) anhydrous or hydrated lower alcohols having 1-4 carbon atoms (eg, methanol, ethanol, propanol, butanol, n-propanol, iso-propanol and n-butanol, etc.), (b) a mixed solvent of the lower alcohol and water, (c) acetone, (d) ethyl acetate, (e) chloroform, (f) 1,3-butylene glycol, (g) hexane , (h) diethyl ether, (i) butyl acetate, or (j) water as an extraction solvent. Alternatively, the Ecklonia cava extract may be a supercritical extract of the Ecklonia plant, for example, CO ₂ may be a supercritical extract of Ecklonia cava.

In one embodiment of the present invention, the Ecklonia cava extract may be an extract obtained by extracting all or at least a part of the Ecklonia cava plant using water, C ₁ to C ₂ lower alcohol or a mixture thereof.

In another embodiment of the present invention, the Ecklonia extract is, for example, 30% to 100% ethanol, 40% to 100% ethanol, 40% to 90% ethanol, 40% to 80% ethanol, 40% to 70% It may be an extract extracted using ethanol, 40% to 60% ethanol, 45% to 60% ethanol, 40% to 55% ethanol, or 45% to 50% ethanol, or 50% ethanol.

In another embodiment of the present invention, the Ecklonia cava extract may be extracted using water or a lower alcohol of C _1-2 , or a mixture thereof, and the Ecklonia cava extract using the water is, for example, hot water. It may be an extract extracted using

In another embodiment of the present invention, the Ecklonia cava extract may be, for example, an extract using water at 40 to 100 ℃, 50 to 100 ℃, 70 to 100 ℃, 80 to 100 ℃.

In another embodiment of the present invention, the Ecklonia cava extract, but is not limited thereto, may be an extract extracted by performing as in the following Examples.

The extraction may include immersing the Ecklonia cava in a solvent for a certain period of time. The extraction may include stirring or heating. The heating may include heating to 50°C, 60°C, 70°C, 80°C, or to a reflux temperature. The heating may be 50°C to reflux temperature, 60°C to reflux temperature, 70°C to reflux temperature, 80°C to reflux temperature, or heating to reflux temperature. The extraction time may vary depending on the selected temperature, and may be 10 hours to 10 days, 10 hours to 5 days, 10 hours to 3 days, or 10 hours to 2 days. The extraction may be reflux extraction of the Ecklonia cava in a solvent. The solvent may have a volume of 1 times, 2 times, 5 times, 10 times, or 15 times or more with respect to the weight of the plant. The solvent may have a volume of 1 to 15 times, 2 to 15 times, 5 to 15 times, 10 to 15 times, or about 15 times the weight of the plant. The Ecklonia may be dried in the shade.

The extraction may also include removing the solvent from the obtained extract by a known method such as concentration under reduced pressure. The extraction may also include preparing a dry extract by drying the obtained extract, such as freeze-drying.

Specifically, the extraction comprises the steps of: mixing the above-ground or underground part of Ecklonia cava with a solvent, incubating, and extracting in a solvent to obtain an extract; filtering the extract in a solvent; and drying the filtered extract under reduced pressure.

As the extraction method, conventional methods in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, pressure extraction, subcritical extraction, supercritical extraction and ultrasonic extraction may be used. For example, it may be a hot water extraction method. The hot water extraction may be one to five extractions. The reduced pressure concentration may be using a vacuum reduced pressure concentrator or a vacuum rotary evaporator. In addition, drying may be vacuum drying, vacuum drying, boiling drying, spray drying or freeze drying.

In one aspect of the present invention, the sarcopenic obesity superficially increases the amount of body fat and at the same time decreases the body muscle mass as a symptom, and as the fat accumulation in the muscle tissue increases, the damage to the muscle cells and tissues increases. And by lowering the function of the muscle, it can be understood as a disease that causes the onset of diseases such as metabolic diseases and cardiovascular diseases.

The sarcopenic obesity increases inflammatory cytokines (TNF-α, IL-6, etc.) from intramuscular fat accumulation, which inhibits muscle protein metabolism to cause a decrease in muscle mass, and also increases insulin resistance, thereby increasing the body As activity decreases and basal metabolic rate decreases, it acts in the direction of increasing body fat again, causing a vicious cycle.

The sarcopenic obesity has a higher prevalence than simple obesity. According to a study using the data from the Korean Longitudinal Study on Health and Aging (KLoSHA), the risk of metabolic syndrome was calculated by regression analysis using ASM/Wt as an index for sarcopenia. On the other hand, the sarcopenic obesity group showed an odds ratio of 8.2 times and that of the obese group 5.5 times, indicating that the prevalence of sarcopenic obesity was higher than that of simple obesity.

The sarcopenic obesity requires a treatment method different from that of simple obesity, specifically by preventing the accumulation of fat in muscle cells or tissues, and at the same time increasing muscle mass and improving the function of the muscle itself, thereby reducing the dysfunction of the patient. It is necessary to resolve and reduce the prevalence of metabolic disorders.

In one aspect of the present invention, the Ecklonia cava extract can be understood to be an active ingredient showing the effect of preventing, improving or treating sarcopenic obesity. Specifically, the Ecklonia cava extract of the present invention may increase muscle mass and exhibit the effect of preventing, improving or treating sarcopenic obesity from inhibiting fat accumulation in muscle tissue.

In one aspect of the present invention, the Ecklonia cava extract inhibits fat accumulation in muscle tissue, for example, it can inhibit damage to muscle cells or tissues due to oxidative stress that may be caused by fat accumulated in the muscle, and also By suppressing the expression of inflammatory cytokines, it is possible to suppress the inflammatory response, thereby preventing damage, death or functional deterioration of muscle cells and tissues, and the Ecklonia cava extract can restore the function of muscle cells and tissues. In addition, the Ecklonia cava extract can prevent, improve or treat sarcopenic obesity by improving muscle mass and muscle strength, and ultimately, diseases caused by sarcopenic obesity, for example, metabolic diseases, cardiovascular diseases, etc. By preventing the risk of onset, there is an effect that can reduce the prevalence of sarcopenic obesity patients.

In another embodiment of the present invention, as a result of ingesting Ecklonia cava extract in an animal model of sarcopenic obesity, it was confirmed that the ratio of muscle mass to total body weight was increased (see FIG. 2 ), calf which is important for body balance and activity of animals It was confirmed that the weight of the muscle and the fluke muscle increased (see FIG. 3 ). In addition, it was confirmed that as a result of ingestion of Ecklonia cava extract in sarcopenic obese animal models, muscle function was also improved by increasing the amount and function (grip strength) of muscles (see FIG. 4 ). In addition, when it was confirmed in the calf muscle tissue of the animal, it was confirmed that the fat accumulation in the muscle tissue was suppressed (see FIG. 5 ).

Therefore, the Ecklonia cava extract of the present invention suppresses intramuscular fat accumulation and increases muscle mass, thereby exhibiting the effect of improving muscle function, and showing the effect of preventing, improving or treating sarcopenic obesity, the bar of the present invention The extract may be provided as a pharmaceutical composition for preventing or treating sarcopenic obesity, and may also be provided as a health functional food composition for preventing or improving sarcopenic obesity.

In another aspect of the present invention, the Ecklonia cava extract may be additionally separated and purified, a fraction, or a fractionated material.

The pharmaceutical composition of the present invention may contain 10 to 95% by weight of the active ingredient, Ecklonia cava extract, based on the total weight of the composition. In addition, the pharmaceutical composition of the present invention may further include at least one active ingredient exhibiting the same or similar function in addition to the active ingredient.

The pharmaceutical composition of the present invention may include a carrier, diluent, excipient or a mixture thereof commonly used in biological agents. Any pharmaceutically acceptable carrier may be used as long as it is suitable for delivering the composition in vivo. Specifically, the carrier is Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, dextrin solution, maltodextrin solution, glycerol, ethanol, or a mixture thereof. In addition, conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed.

When formulating the composition, commonly used fillers, extenders, binders, wetting agents, disintegrants, diluents or excipients such as surfactants may be added.

The composition of the present invention may be formulated as an oral preparation or a parenteral preparation. Oral formulations may include solid formulations and liquid formulations. The solid preparation may be a tablet, pill, powder, granule, capsule, or troche, and the solid preparation may be prepared by adding at least one excipient to the composition. The excipient may be starch, calcium carbonate, sucrose, lactose, gelatin, or a mixture thereof. In addition, the solid formulation may contain a lubricant, examples of which include magnesium stearate, talc, and the like. Meanwhile, the liquid formulation may be a suspension, an internal solution, an emulsion, or a syrup. In this case, the liquid formulation may include excipients such as wetting agents, sweetening agents, fragrances, and preservatives.

The parenteral formulation may include injections, suppositories, powders for respiratory inhalation, aerosols for sprays, powders and creams, and the like. The injection may include a sterile aqueous solution, a non-aqueous solution, a suspension solution, an emulsion, and the like. In this case, as the non-aqueous solvent or suspension solution, vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, or injectable esters such as ethyl oleate may be used.

The composition of the present invention may be administered orally or parenterally depending on the purpose. Parenteral administration may include intraperitoneal, rectal, subcutaneous, intravenous, intramuscular or intrathoracic injection.

The composition may be administered in a pharmaceutically effective amount. This may vary depending on the type of disease, severity, drug activity, patient's sensitivity to the drug, administration time, administration route, treatment period, drugs used at the same time, and the like.

Furthermore, the present invention provides a method for preventing or treating sarcopenic obesity, comprising administering to a subject in a therapeutically effective amount the Ecklonia cava extract, a fraction thereof, or an active ingredient thereof.

In this case, the therapeutically effective amount refers to an amount capable of improving, treating, preventing or ameliorating the symptoms or conditions of a subject when administered into the body, depending on the administration method. In addition, the amount may be different depending on the weight, age, sex, condition, and family history of the subject to be administered, and in the present invention, the treatment method may determine a different dosage according to different conditions for each subject. The "effective amount" is, for example, an amount effective to treat a disease.

The term “subject,” as used herein, refers to an animal, such as a mammal, such as a human.

In addition, the present invention provides a use of the Ecklonia cava extract in the manufacture of a pharmaceutical composition for the prevention or treatment of sarcopenic obesity.

Furthermore, the present invention provides a health functional food composition for preventing or improving sarcopenic obesity containing Ecklonia cava extract as an active ingredient.

In addition, the present invention provides a health functional food composition for improving muscle function containing Ecklonia cava extract as an active ingredient.

Ecklonia cava extract according to the present invention is as described above. As used herein, the term “health functional food” refers to a food manufactured using raw materials or ingredients that are easily deficient in daily meals or have a useful function in the human body, and refers to food that helps maintain human health, but is limited thereto. It is not used and is used in the meaning of including all health foods in the normal sense.

The form and type of health functional food is not particularly limited. Specifically, the health functional food may be in the form of tablets, capsules, powders, granules, liquids and pills. The health functional food may include various flavoring agents, sweetening agents, or natural carbohydrates as additional ingredients. The sweetener may be a natural or synthetic sweetener, and examples of the natural sweetener include thaumatin, stevia extract, and the like. Meanwhile, examples of synthetic sweeteners include saccharin, aspartame, and the like. In addition, the natural carbohydrates may be monosaccharides, disaccharides, polysaccharides, oligosaccharides and sugar alcohols.

The health functional food of the present invention, in addition to the above-described additional ingredients, nutrients, vitamins, electrolytes, flavoring agents, colorants, pextan and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives , glycerin, alcohol, and the like may be further included. These components may be used independently or in combination.

Hereinafter, the present invention will be described in detail through Examples and Experimental Examples.

However, the Examples and Experimental Examples described below are merely illustrative of the present invention in detail in one aspect, and the present invention is not limited thereto.

<Example 1> Preparation of 50% alcohol Ecklonia cava extract

In order to prepare the Ecklonia cava extract according to the present invention, it was carried out as follows.

Specifically, E. coli raw material was prepared as an extraction raw material, and the extraction was carried out using the same volume of extraction raw material (25 g of E. coli extract) and a solvent (1000 ml). After extraction with 50% alcohol for 12 hours, it was filtered using a decanter. After concentration and ethanol recovery, sterilization and drying were performed at 87°C for 40-60 minutes. Then, 20% dextrin was added and spray dried. All extract manufacturing processes were carried out at Aqua Greentech Co., Ltd. (Jeju, Korea).

<Example 2> Preparation of 40% alcohol Ecklonia cava extract

In order to prepare the Ecklonia cava extract according to the present invention, it was carried out as follows.

Specifically, E. coli raw material was prepared as an extraction raw material, and the extraction was carried out using the same volume of extraction raw material (25 g of E. coli extract) and a solvent (1000 ml). After extraction with 40% alcohol for 12 hours, it was filtered using a decanter. After concentration and ethanol recovery, sterilization and drying were performed at 87°C for 40-60 minutes. Then, 20% dextrin was added and spray dried. All extract manufacturing processes were carried out at Aqua Greentech Co., Ltd. (Jeju, Korea).

<Example 3> Preparation of 70% alcohol Ecklonia cava extract

In order to prepare the Ecklonia cava extract according to the present invention, it was carried out as follows.

Specifically, E. coli raw material was prepared as an extraction raw material, and the extraction was carried out using the same volume of extraction raw material (25 g of E. coli extract) and a solvent (1000 ml). After extraction with 70% alcohol for 12 hours, it was filtered using a decanter. After concentration and ethanol recovery, sterilization and drying were performed at 87°C for 40-60 minutes. Then, 20% dextrin was added and spray dried. All extract manufacturing processes were carried out at Aqua Greentech Co., Ltd. (Jeju, Korea).

<Experimental Example 1> Identification of optimal extraction conditions for Ecklonia cava extract

In the Ecklonia cava extract of the present invention, in order to further improve the industrial applicability, the optimal extraction conditions of the Ecklonia cava extract were compared and evaluated as follows.

Specifically, the extraction yield was derived by measuring the weight of the powdered E. coccyx extract, finally obtained under each different extraction conditions performed in Example 1, and by comparative evaluation, the optimal extraction conditions of the Ecklonia cava extract of the present invention were elucidated. did.

The extraction yield calculated from each of the three conditions (40%, 50%, and 70% alcohol) is shown in FIG. 1 .

Referring to Figure 1, it can be seen that the yield of the Ecklonia cava extract extracted under the extraction conditions of 50% alcohol (room temperature, 12 hours) is the best.

Therefore, in order to provide the extract of the present invention in a direction with high industrial applicability or as a large-capacity extract on an industrial scale, the method using 50% alcohol was most preferable, so the animal model used in the present invention is 50% of E. The efficacy was evaluated by oral administration of the extract.

<Experimental Example 2> Measurement of muscle mass in total body weight according to ingestion of Ecklonia cava extract in sarcopenic obesity model

With respect to the ratio of muscle mass to the total body weight of the sarcopenic obesity model, an experiment was conducted as follows in order to confirm the change according to the intake of Ecklonia cava extract according to the present invention.

<2-1> Production of sarcopenic obesity model

First, in order to produce a sarcopenic obese animal model, the management and use of laboratory animals was reviewed by the Animal Experimental Ethics Committee (IACUC) of the Gachon University Lee Gil-Yeo Cancer Diabetes Research Institute as a standard suitable for the guidelines of the International Association for Accreditation of Laboratory Animal Care (AAALAC). and the approved protocol.

A diet induced obesity (DIO) model induced by ingestion of a 45% high fat diet (High fat diet, cat. D12451. Research diet company) for 8 weeks was prepared. In order to confirm the effect of Ecklonia cava extract, 20-25 g of 8-week-old male C57BL/6N mice were selected. After acclimatization to the animal room breeding environment for 1 week, the mice were divided into a normal control diet (NFD) and a high-fat diet group. The group fed together with a high fat diet and 0.9% saline for the remaining 4 weeks while feeding (DIO-saline) and the group fed together with 50% extract of Ecklonia cava (50 mg/kg, 100 mg/kg) by concentration (DIO) -ECE50, ECE100) and proceeded.

<2-2> Measurement of body weight and muscle mass in sarcopenic obesity model

For the normal diet group (Control), the sarcopenic obesity model (DIO-saline) and the Ecklonia cava extract ingestion group (DIO-ECE50, ECE100) prepared in <2-1> above, the body weight was measured, respectively, and the muscle mass was It was measured using dual energy X-ray absorptiometry (DEXA), which has been spotlighted as a diagnostic method for sarcopenia due to its low radiation dose and test convenience, and the results are shown in FIG. 2 .

Referring to Figure 2, it was confirmed that the ratio of body weight to muscle mass was about 50% in the high-fat diet-eating animal, which is a sarcopenic obesity model, and that compared with the normal control group, the whole-body muscle mass was significantly reduced in the high-fat diet intake animal. became However, it was confirmed that in the experimental group (DIO-ECE50, ECE100) ingesting the 50% extract of Ecklonia cava alcohol of the present invention, the ratio of muscle mass to total body weight was significantly increased.

<Experimental Example 3> Measurement of the weight of calf muscle and fluke muscle according to ingestion of Ecklonia cava extract in sarcopenic obesity model

By measuring the weights of the gastrocnemius and soleus muscles, which are the main muscles directly related to gait and body balance in the sarcopenic obesity model, the change in the ratio of the calf muscle to the soleus muscle was confirmed. The results are shown in FIG. 3 .

Referring to FIG. 3 , the ratio of calf muscle was confirmed to be about 38% and the ratio of sole muscle was confirmed to be less than 2% of the total body weight of the high fat diet intake animal (DIO-saline), which is a sarcopenic obesity model, a normal control group. Compared with (Control), it was confirmed that the calf muscle and sole muscle, which are important for gait and body balance, were significantly reduced. However, in the experimental group (DIO-ECE50, ECE100) ingesting the 50% extract of Ecklonia cava according to the present invention, it was confirmed that both the calf muscles and the fluke muscles significantly increased, thereby recovering to a level close to that of the normal control group.

<Experimental Example 4> Measurement of grip according to ingestion of Ecklonia cava extract in sarcopenic obesity model

In order to confirm that the muscle function is restored from ingestion of the Ecklonia cava extract according to the present invention in the sarcopenic obesity model, grip strength was measured.

Specifically, to measure the grip strength, use a grip strength meter to measure the forelimbs by having the animal hold the bar with its toes and after confirming that the animal is firmly grasped, hold the tail origin of the animal and maintain the body horizontally at a constant speed (2.5 cm per second). Record the reading displayed on the gauge at the time the pull bar is released. Measurement of the hind legs is carried out in the same way as above by holding the animal's abdomen and pulling it toward the tail. Each of the hind legs and the forelimbs was measured and recorded twice, and the average value is shown in FIG. 4 .

Referring to FIG. 4 , the gripping power was confirmed to be about 7 gf/g in the high fat diet intake animal (DIO-saline), which is a model of sarcopenic obesity, and it was confirmed that the gripping power was significantly reduced compared to the normal control group (Control). However, in the experimental group (DIO-ECE50, ECE100) ingesting the 50% extract of Ecklonia cava alcohol of the present invention, it was confirmed that the grasping power was significantly increased and recovered to a level close to that of the normal control group.

<Experimental Example 5> Evaluation of fat accumulation in muscle tissue in sarcopenic obesity model

In order to confirm that fat accumulation in muscle tissue is suppressed from ingestion of the Ecklonia cava extract according to the present invention in a sarcopenic obesity model, an experiment was conducted as follows.

As a method to evaluate the degree of fat accumulation in muscle tissue, Oil-Red O staining that specifically responds to lipid droplets was performed. As a method, the frozen section tissue was sliced and the slide attached to the coated slide was dried in an oven at 37° C. for 5 minutes and then hydrated in tertiary distilled water to remove the embedding media. Dye in absolute polyethylene glycol (solute propylene glycol) for 3 minutes, 0.5% Oil-Red O sample (0.5 g Oil-Red O powder and 100 ml absolute propylene glycol) for 10 hours at room temperature, and oil- with 85% polyethylene glycol After removing Red O, it was hydrated twice in tertiary distilled water. In order to observe the nucleus of the muscle tissue, DAPI (Sigma) was treated for 3 minutes, washed with PBS buffer 3 times for 10 minutes each, and then sealed with aqueous mounting media. The images were taken using a laser confocal microscope, and are shown in FIG. 5 .

Referring to Figure 5, fat accumulation in calf muscle tissue in a high-fat diet-eating animal (DIO-saline), a sarcopenic obesity model, is indicated by a red spot in the (A) picture and (B) the Oil-Red O intensity in the measured graph. As can be seen, it was confirmed that the amount of fat accumulated in the muscle tissue was greatly increased by about 5 to 6 times or more compared to the normal control group (Control). However, in the experimental group (DIO-ECE50, ECE100) ingesting the 50% extract of Ecklonia cava according to the present invention, the amount of fat accumulated in the muscle tissue was significantly reduced as well as the intake dose-dependently, close to that of the normal control group. was confirmed to be recovering.

Therefore, as can be seen from the above-described experimental examples and drawings referenced herein, the Ecklonia cava extract according to the present invention can reduce the amount of fat accumulated in muscle tissue while increasing the muscle mass of sarcopenic obese patients. It is possible to suppress oxidative stress or inflammatory response caused by fat accumulated in muscles, prevent damage to muscle cells and tissues, restore muscle function, and prevent, improve or treat sarcopenic obesity show the effect. In addition, ultimately, there is a useful effect that can improve the quality of life of patients by reducing the risk of developing metabolic diseases or cardiovascular diseases.

Claims (15)

A pharmaceutical composition for preventing or treating sarcopenic obesity, comprising Ecklonia cava extract as an active ingredient.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for the prevention or treatment of sarcopenic obesity, characterized in that it is extracted with water, a C1 to C2 lower alcohol or a mixed solvent thereof.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for the prevention or treatment of sarcopenic obesity, characterized in that the Ecklonia cava extract is extracted with 40% to 70% ethanol.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for preventing or treating sarcopenic obesity, characterized in that it suppresses fat accumulation in muscle tissue.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for preventing or treating sarcopenic obesity, characterized in that it increases muscle mass or improves muscle function.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for preventing or treating sarcopenic obesity, characterized in that it suppresses oxidative stress or inflammatory response caused by fat accumulated in muscle tissue.
A health functional food composition for preventing or improving sarcopenic obesity, comprising Ecklonia cava extract as an active ingredient.
8. The method of claim 7,
The Ecklonia extract is water, C1 to C2 lower alcohol, or a health functional food composition for the prevention or improvement of sarcopenic obesity, characterized in that extracted with a mixed solvent thereof.
8. The method of claim 7,
The Ecklonia cava extract is a health functional food composition for preventing or improving sarcopenic obesity, characterized in that it is an Ecklonia cava extract extracted with 40% to 70% ethanol.
8. The method of claim 7,
The Ecklonia cava extract is a health functional food composition for preventing or improving sarcopenic obesity, characterized in that it suppresses fat accumulation in muscle tissue.
According to claim 1,
The Ecklonia cava extract is a pharmaceutical composition for preventing or treating sarcopenic obesity, characterized in that it increases muscle mass or improves muscle function.
A health functional food composition for improving muscle function containing Ecklonia cava extract as an active ingredient.
13. The method of claim 12,
The Ecklonia cava extract is a health functional food composition for improving muscle function, characterized in that the muscle function is improved by increasing the muscle mass or inhibiting the accumulation of fat in the muscle tissue.
13. The method of claim 12,
The Ecklonia cava extract suppresses oxidative stress or inflammatory response caused by fat accumulated in muscle tissue, and improves muscle function by preventing damage to muscle cells or tissues, health functional food for improving muscle function composition.
15. The method of claim 13 or 14,
The improvement of the muscle function is a health functional food composition for improving muscle function, characterized in that the improvement of muscle strength.

Images